Frost Radar™: Global Clinical Trial IT Solutions Market, 2022

Healthcare Frost Radar™: Global Clinical Trial IT Solutions Market, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
17-Aug-2022
REGION
North America
Deliverable Type
Frost Radar
Research Code: MGAA-01-00-00-00
SKU: HC03572-NA-MR_26810
Yes
PDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03572-NA-MR_26810

Frost Radar™: Global Clinical Trial IT Solutions Market, 2022
Published on: 17-Aug-2022 | SKU: HC03572-NA-MR_26810

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

COVID-19 has accelerated the need for a faster, more accessible clinical trial process. During the height of the pandemic, in-person follow-ups for ongoing trials were replaced with hand-held devices that essentially built an ecosystem for home health care support services that can be easily leveraged to avoid or reduce participant dropout rates.

To improve clinical trial efficiency, pharma companies are turning towards cloud-based electronic data capture (EDC), randomization and trial supply management (RTSM), and integrated platforms that offer them a unified trial workflow view.? Major companies are exploring technologies to achieve more than 30% cost reductions by 2025, more than 50% performance efficiency by 2030, and more than 40% virtual/hybrid trials by 2040.

In the biopharmaceutical industry, personalized intervention and technologies to support outcomes measurement drive clinical development, a departure from the traditional value-driven development model. As such, participants must realign their go-to-market strategies to optimize the end-to-end customer experience.

Today, the industry strives to build an inclusive partner ecosystem that will integrate technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. Doing so will drive adoption of decentralized clinical trials (DCTs) and reduce the burden on investigators and sites during the next 3 to 5 years.

Frost & Sullivan’s research indicates that using their experience deploying electronic clinical (eClinical) solutions, vendors can create smart and connected IT solutions that focus on decentralized and virtual hybrid trials.

The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned.

Author: Aarti Siddhesh Chitale

Strategic Imperative

Growth Environment

Frost Radar™: Clinical Trial IT Solutions Market

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Advarra

Anju Software

ArisGlobal

Castor

Clario

Datatrak

DSG

ICON

IQVIA

Labcorp (Covance)

3DS (Medidata)

Mednet

Medrio

Oracle Corporation

REDCap Cloud

Signant Health

Thermo Fisher Scientific (PPD)

Veeva Systems

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

COVID-19 has accelerated the need for a faster, more accessible clinical trial process. During the height of the pandemic, in-person follow-ups for ongoing trials were replaced with hand-held devices that essentially built an ecosystem for home health care support services that can be easily leveraged to avoid or reduce participant dropout rates. To improve clinical trial efficiency, pharma companies are turning towards cloud-based electronic data capture (EDC), randomization and trial supply management (RTSM), and integrated platforms that offer them a unified trial workflow view.​ Major companies are exploring technologies to achieve more than 30% cost reductions by 2025, more than 50% performance efficiency by 2030, and more than 40% virtual/hybrid trials by 2040. In the biopharmaceutical industry, personalized intervention and technologies to support outcomes measurement drive clinical development, a departure from the traditional value-driven development model. As such, participants must realign their go-to-market strategies to optimize the end-to-end customer experience. Today, the industry strives to build an inclusive partner ecosystem that will integrate technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. Doing so will drive adoption of decentralized clinical trials (DCTs) and reduce the burden on investigators and sites during the next 3 to 5 years. Frost & Sullivan’s research indicates that using their experience deploying electronic clinical (eClinical) solutions, vendors can create smart and connected IT solutions that focus on decentralized and virtual hybrid trials. The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Author: Aarti Siddhesh Chitale
More Information
Deliverable Type Frost Radar
Author Aarti Siddhesh Chitale
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 cell and gene therapy market
Podcast No
WIP Number MGAA-01-00-00-00